SLS vs STOK Stock Comparison
SLS currently leads STOK in this stock comparison, with AIQ scores of 57 vs 42. The clearest difference is quality, while STOK has the stronger risk resilience profile.
What is the main difference between SLS and STOK?
SLS leads the current stock comparison as SELLAS Life Sciences Group, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
SELLAS Life Sciences Group, Inc. vs Stoke Therapeutics, Inc.
SLS leads
SLS leads by 15 AIQ points, primarily on Quality and Momentum, but the lead has narrowed from 33 points over 30 sessions.
Fragile: 2 of 4 evidence groups support SLS, its lead is narrowing, and its current signal state is conflicted.
SELLAS Life Sciences Group, Inc.
Stoke Therapeutics, Inc.
The Algovestiq AIQ Score currently favors SLS over STOK, 57 versus 42 as of Nov 15, 2026. SLS's advantage is driven primarily by stronger quality and momentum, while STOK holds the stronger risk resilience profile. SLS also shows the weaker technical structure relative to its 50-day moving average. 2 of 4 covered evidence groups favor SLS today, and the comparison is rated Fragile on stability: only 2 of 4 covered evidence groups agree. SLS lead: Weakening — the AIQ differential moved from 33 to 15 points over 30 sessions.
Compare SELLAS Life Sciences Group, Inc. and Stoke Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare SLS and STOK against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality73 vs 42SLS +31
- Risk Resilience32 vs 59STOK +27
- Momentum55 vs 47SLS +8
2 of 4 evidence groups favor SLS. SLS’s edge is concentrated in quality and momentum; STOK keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +2, not enough on its own to move the overall score.
New signals
- Distribution Pattern — bearish, volume, medium horizon (1.48x)
Largest factor move: Momentum +1, not enough on its own to move the overall score.
New signals
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- RSI Midline Reclaim — bullish, momentum, short horizon
SLS's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — SLS and STOK both carry a full feed there.
The central trade-off
SLS (SELLAS Life Sciences Group, Inc.): the stronger current systematic profile, led by quality and momentum.
STOK (Stoke Therapeutics, Inc.): the counter-case, on risk resilience, technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
SLSSLS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
STOKSTOK on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
SLSSLS on the Momentum factor, by 8 points.
Lower downside
STOKSTOK on Risk Resilience, by 27 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | SLS | STOK | Note |
|---|---|---|---|
| Implied upside to target | — | +61.2% | Level |
| Target dispersion | — | 0% | Lower is tighter analyst agreement |
| Consensus | Strong Buy | Buy | Context, not a primary driver |
| Analysts covering | 2 | 14 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 4 covered evidence groups favor SLS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | SLS | 57 vs 42 |
| Fundamentals | SLS | TTM ROE -7.7% vs -20.9% |
| Valuation | Not covered | Not covered |
| Technicals | STOK | Price vs 50-day -28.7% vs 0.9%; vs 200-day -10.5% vs -13.3% |
| Risk Resilience | STOK | Risk Resilience 32 vs 59 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of SLS and STOK and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is wide at 15 points. (supports the conclusion holding)
- Only 2 of 4 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has swung materially session to session. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SLS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13SLS lead: Weakening — the AIQ differential moved from 33 to 15 points over 30 sessions.
- Today
- SLS +15
- 57 vs 42
- 7 sessions ago
- SLS +25
- 65 vs 40
- 30 sessions ago
- SLS +33
- 69 vs 36
- 90 sessions ago
- SLS +32
- 76 vs 44
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 2 bearish / 1 neutral, conflicted
Only SLS
- Golden Cross Active — bullish, trend, long horizon (25.60%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- Distribution Pattern — bearish, volume, medium horizon (1.48x)
3 bullish / 2 bearish / 2 neutral, conflicted
Only STOK
- Death Cross Active — bearish, trend, long horizon (16.39%)
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.31x)
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- RSI Midline Reclaim — bullish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
SLS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.12%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.83%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1STOK closes the Quality gap — currently 31 points behind, the largest single contributor to SLS's edge.
- 2STOK's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3SLS's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
- 4The narrowing continues — the lead has already given back 18 points over 30 sessions, and a further 15-point move would eliminate SLS's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
SLS leads on balance| Metric | SLS | STOK |
|---|---|---|
| Revenue growth (YoY) | 0% | 20.7% |
| EPS growth (YoY) | 0% | -16.1% |
| Gross margin | 0% | 88.5% |
| Operating margin | 0% | -9.1% |
| Return on equity (TTM) | -7.7% | -20.9% |
| Debt to equity | 0 | 0 |
Performance
Split across windows| Metric | SLS | STOK |
|---|---|---|
| 1 week (5 sessions) | -6.7% | 0.5% |
| 1 month (20 sessions) | -21.2% | 10.4% |
| 3 months (63 sessions) | -39.5% | -17% |
| 6 months (126 sessions) | 11% | -11.3% |
| Year to date | 108.5% | -15.9% |
| 1 year (252 sessions) | 427.5% | 6.2% |
Technicals
STOK has the stronger structure| Metric | SLS | STOK |
|---|---|---|
| RSI (14) | 34.7 | 51.3 |
| ADX (14) | 25.3 | 17.3 |
| Price vs 50-day | -28.7% | 0.9% |
| Price vs 200-day | -10.5% | -13.3% |
| Volatility (1M, annualized) | 114.5% | 48.9% |
Risk
STOK is the more resilient| Metric | SLS | STOK |
|---|---|---|
| Beta | 2.27 | 0.96 |
| Sharpe ratio | 2.04 | 0.23 |
| Sortino ratio | 3.43 | 0.35 |
| Max drawdown | -49.2% | -41.3% |
| Current drawdown | -49.2% | -30.4% |
| Annualized volatility | 109.9% | 53.2% |
| Value at risk (95%) | -8.9% | -5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, SLS or STOK?
On the Algovestiq AIQ Score, SLS is the stronger of the two as of Nov 15, 2026, scoring 57 against STOK's 42. The edge comes from quality and momentum. STOK is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is SLS or STOK the better buy right now?
SLS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 4 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor SLS over STOK?
The composite weights Quality, Value, Momentum and Risk Resilience. SLS leads Quality by 31 points; STOK leads Risk Resilience by 27 points; SLS leads Momentum by 8 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, SLS or STOK?
Analyst price targets imply not covered upside for SLS and +61.2% for STOK. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, SLS or STOK?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, SLS or STOK?
STOK on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, SLS or STOK?
SLS on the Momentum factor, by 8 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, SLS or STOK?
STOK is the more resilient of the two, so the other name carries the higher downside risk. STOK on Risk Resilience, by 27 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is SLS more profitable than STOK?
SLS leads on the comparable margin measures — gross margin 0% vs 88.5%; operating margin 0% vs -9.1%; ttm roe -7.7% vs -20.9%.
Is SLS's lead over STOK getting stronger or weaker?
SLS lead: Weakening — the AIQ differential moved from 33 to 15 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the SLS vs STOK verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: STOK closes the Quality gap — currently 31 points behind, the largest single contributor to SLS's edge; STOK's Death Cross Active resolves — a bearish trend rule currently active against it; SLS's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 18 points over 30 sessions, and a further 15-point move would eliminate SLS's advantage entirely.
What do the current signals say about SLS and STOK?
SLS: 1 bullish / 2 bearish / 1 neutral, conflicted. STOK: 3 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on SLS is Golden Cross Active (bullish, long horizon). On STOK it is Death Cross Active (bearish, long horizon).
Compare SLS and STOK with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.